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A rapid liquid chromatography electrospray ionization mass spectrometry (LC/ESI-MS) method 
with good sensitivity and specificity has been developed and validated for the identification and 
quantification of trimetazidine in human plasma. Trimetazidine and lidocaine (internal standard) 
were isolated from plasma samples by protein precipitation with methanol. The chromatographic 
separation was accomplished on a Xterra MS C18 Column (150 mm × 4.6 mm, 5 μm particle 
size) with the mobile phase consisting of methanol and water (40:60, v/v) (pH 2.0, adjusted with 
trifluoroacetic acid), and the flow rate was set at 0.6 mL/min. Detection was performed on a 
single quadruple mass spectrometer by selected ion monitoring (SIM) mode (m/z 267.0 for 
trimetazidine and m/z 235.0 for lidocaine) with the retention time at about 3.47 and 5.05 min, 
respectively. The calibration curve for trimetazidine was satisfactory with regression coefficient 
0.9995 over the range of 2.5–100 ng/mL in the plasma. The LOQ (S/N = 10) was accordingly 
2.5 ng/mL. The intra-day and inter-day precision expressed as relative standard deviation was 
2.83–6.10% and 4.83–5.82%. The method was successfully applied to investigate the 
bioequivalence between two kinds of tablets (test versus reference product) in 19 healthy male 
Chinese volunteers. After a single 20 mg dose for the test and reference product, the resulting 
mean of major pharmacokinetic parameters such as AUC0–24, AUC0−∞, Cmax,Tmax and t1/2 of 
trimetazidine were (673.1 ± 117.6 ng h mL−1 versus 652.3 ± 121.9 ng h mL−1), 
(717.1 ± 120.9 ng h mL−1 versus 692 ± 128.6 ng h mL−1), (74.85 ± 12.13 ng mL−1 versus 
71.93 ± 14.32 ng mL−1), (2.312 ± 0.663 h versus 2.211 ± 0.608 h) and (4.785 ± 0.919 h versus 
4.740 ± 0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in 




Trimetazidine [1-(2,3,4-trimethoxybenzyl) piperazine dihydrochloride] is a clinically effective 
anti-anginal agent. By switching energy substrate preference from fatty acid oxidation to glucose 
oxidation [1,2], it has a direct anti-ischaemic effect on the myocardium without affecting 
myocardial oxygen consumption and coronary blood flow [3]. 
 
Several methods have been investigated for the determination of trimetazidine. For example, 
Courte and Bromet [4] developed a quantitative method using HPLC coupled with fluorescence 
detection and Fay et al. [5] determined trimetazidine with GC/MS. Both methods were very 
labor-intensive and time-consuming because of the required derivatization procedures. Min et al. 
[6] reported a HPLC method coupled with a liquid–liquid extraction procedure for sample clean-
up, which, unfortunately, was obviously not suitable for the study of bioequivalence due to the 
relatively higher LOQ (10 ng/mL). De Jager et al. [7] developed a LC/MS-MS method, despite 
the claim of relative short turn-round time, avoiding the use of internal standard made some 
concern of reproducibility. Recently, Medvedovici et al. [8] developed a LC/APCI-MS-MS 
method for the determination of trimetazidine, however, the application of tandem mass is 
relative high-cost and operationally complex. In this study, a rapid LC/ESI-MS method coupled 
with a simple sample preparation was developed and validated, and it has been successfully 
applied to a bioequivalent study on Chinese population. 
 
Although the pharmacokinetics and clinical pharmacology of trimetazidine have been thoroughly 
studied, there is little data on Chinese population. Therefore, a new HPLC/ESI-MS method for 
the determination of trimetazidine in plasma samples was developed, in order to carry out a 
pharmacokinetic and bioequivalence study of two immediate release trimetazidine formulations 
in healthy male Chinese volunteers. 
 
MATERIALS AND METHODS 
Reagents 
The trimetazidine reference was supplied by JiangSu WuZhong Chinese Traditional Medicine 
R&D Co., Ltd. and lidocaine reference substances were purchased from the National Institute for 
the Control of Pharmaceutical and Biological Products (Beijing, China). Methanol (HPLC grade) 
was commercially obtained from Merck (Germany). All the other chemicals were analytical 
grade. Ultra pure water was supplied by Millipore Simplicity™ system (MA, USA). The drug-
free human plasma was obtained from Shanghai Blood Center (Shanghai, China). 
 
Subjects 
A total of 19 healthy male Chinese volunteers were enrolled in this study in the Shanghai Jing-
An Central Hospital, Shanghai. The mean age was 22.5 ± 2.1 year old with a range of 20–26 
years and mean body weight was 64.5 ± 7.7 kg with a range of 52–80 kg. The volunteers were 
free from significant cardiac, hepatic, renal, pulmonary, neurologic, gastrointestinal and 
hematologic disease, as assessed by physical examination, electrocardiography and the 
laboratory tests including hematology, biochemistry, electrolytes and urinalysis. None had a 
history or evidence of hepatic, renal, gastrointestinal or hematologic abnormality or any acute or 
chronic diseases or allergy to any drug. All the subjects were instructed to abstain from taking 
any medication for 2 weeks before and during the overall study period and signed the informed 
consents. The study protocols were approved by the relevant Ethical Review Committee in 
accordance with the principles of the Declaration of Helsinki, and the recommendations of the 
State Food and Drug Administration of China. 
 
Formulations 
The test preparation was trimetazidine tablets (Batch No. 000323), which was supplied by 
Jiangsu WuZhong Pharmaceutical Co., China. The reference preparation was trimetazidine 
tablets (Batch No. 4K4514), which was commercially obtained from Servier Pharmaceutical Co., 
France. Both preparations were labeled to contain 20 mg of trimetazidine. 
 
Study design 
The 19 volunteers participated in a single dose crossover bioequivalence study with a 1-week 
interval between each administration. Each subject received one trimetazidine test tablet or 
reference tablet randomly. After an overnight fasting (over 10 h), volunteers were given a single 
dose of either formulation (reference or test) of trimetazidine with 250 mL of water. Water intake 
was permitted 2 h after treatment while food was not allowed until 4 h after treatment. In 
addition, water, lunch and dinner were given to all the volunteers according to the specially 
designed schedule. About 4 mL venous blood samples were collected into heparinized 
polypropylene tubes at pre-dose (0 h), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 h after treatment. 
Blood samples were immediately centrifuged at 3000 × g for 10 min at 4 °C, and the separated 
plasma was stored frozen at −20 °C until assayed. 
 
Equipment 
The experiments were carried out with an Agilent 1100 system. The system consisted of a 
G1312A binary pump, a G1322A mobile phase vacuum degassing unit, a G1313A autosampler, 
a G 1316A temperature-controlled column compartment and a G1946A single quadruple mass 
spectrometric (MS) detector equipped with an ESI ion source. Data were acquired and integrated 
by the ChemStation. A Waters Xterra MS C18 (150 mm × 4.6 mm, 5 μm) was used for the 
separation. 
 
Chromatographic and MS conditions 
Chromatographic separation was achieved using a mobile phase consisting of methanol and 
water (40:60, v/v; pH 2.0, adjusted with trifluoroacetic acid), and the elution rate was 
0.6 mL/min. The analytical column was kept at 40 °C. Electrospray ionization was performed 
using nitrogen as nebulizing gas at 9.0 L/min flow rate, 40 psi nebulizing pressure and 350 °C 
drying gas temperature. Capillary voltage was set at 3000 V. Optimum fragment voltage of 70 V 
was selected after varying between 50 and 190 V. Positive-ion selected ion monitoring (SIM) 
mode was used to detect m/z 267.0 ([Trimetazidine +H]+) and m/z 235.0 ([Lidocaine +H]+). 
 
Standards 
Stock solutions of trimetazidine (400 μg/mL) and the I.S. (lidocaine, 1 mg/mL) were prepared 
using the mobile phase. The working I.S. solution (1000 ng/mL) was freshly prepared using 
mobile phase prior to each batch assay. 
 
Sample preparations 
Each 500 μL of aliquot plasma and 50 μL of lidocaine solution (1000 ng/mL) were added into a 
5.0 mL glass tube. The sample was vortexed for 30 s, and then deproteinated by addition of 
1.0 mL methanol. The resulting mixture was centrifuged at 4000 × g for 8 min. The supernatant 
was acidified with 30 μL of trifluoroacetic acid (1:5, v/v), and subsequently dried in a rotational-
vacuum-concentrator at 50.0 ± 0.5 °C. The residue was re-dissolved in 200 μL of mobile phase, 
and a 90 μL aliquot was injected into the LC/MS system. 
 
Validation and calibration 
The calibration curves were constructed routinely for spiked plasma containing 2.5, 5, 10, 20, 40, 
80 and 100 ng/mL of trimetazidine during the process of validation and the study as well. 
Similarly, quality control samples were prepared in spiked plasma containing 5, 20 and 
80 ng/mL of trimetazidine. Accuracy was assessed as follow: Bias (%) = ((concentration 
added − concentration detected)/concentration added) × 100. 
 
Pharmacokinetics and statistical analysis 
Pharmacokinetic analysis was performed using a non-compartmental method. Peak of the ratio 
of trimetazidine concentrations to lidocaine concentration (Cmax) and the time to Cmax (Tmax) 
were determined by inspection of the individual plasma concentration–time profiles of the drug. 
The area under the plasma concentration–time curve (AUC) from the time of drug administration 
to the last plasma sampling time (AUC0−t) was calculated according to the linear trapezoidal 
rule. The AUC from 0 to infinity (AUC0−∞) was calculated as AUC0−∞ = AUC + Ct/λz (where Ct 
is the last plasma concentration measured). The elimination rate constant (λz) was determined by 
linear regression analysis of the log-linear part of the plasma concentration–time curve. The half-
life (t1/2) of trimetazidine was obtained by t1/2 = ln 2/λz. 
 
Bioequivalence of the two trimetazidine products was assessed by calculating individual AUC0−t, 
AUC0−∞, Cmax and Tmax values. Their ratios (test versus reference) of log-transformed data, 
together with their means and 90% confidence intervals, were analyzed with analysis of variance 
(ANOVA) using a commercially software package named Drug And Statistics (DAS, Version 
1.0, recommended by Mathematical Pharmacology Professional Committee of China). If the 
parameters between the two preparations was not statistically different with each other 
(P ≥ 0.05), and the 90% confidence interval for the parameters located within 80–125%, the two 
drugs would be considered as the bioequivalent preparations. 
 
RESULTS AND DISCUSSION 
Typical chromatograms of test plasma samples were shown (Fig. 1). The retention time for 
trimetazidine and lidocaine (I.S.) were 3.47 and 5.05 min, respectively. No endogenous 
interference was observed with either trimetazidine or lidocaine. 
 
 
Figure 1: Chromatograms of trimetazidine and lidocaine in plasma at SIM mode; (1) blank plasma; (2) a spiked 
plasma sample with trimetazidine (40 ng/mL) and lidocaine(1000 ng/mL); (3) test plasma sample (containing 
42 ng/mL trimetazidine); retention time was 3.47 min for trimetazidine and 5.05 min for lidocaine, respectively. 
 
 
The mean recovery of the extraction was determined by comparing the peak area obtained from 
the plasma sample with peak area obtained by the direct injection of pure drug standard solution 
at four different concentration levels. The mean recovery of trimetazidine was over 72% (Table 
1). 
 
Table 1: Recovery of trimetazidine in plasma 
Plasma concentration (ng/mL) Recovery (%) Mean (%) R.S.D. (%) 
2.5 74.1 70.5 76.1 73.3 73.7 73.5 2.71 
5 70.1 74.3 71.6 73.0 72.3 72.2 2.17 
20 77.4 75.8 67.7 75.6 77.0 74.7 5.34 
80 75.3 81.9 83.4 78.4 83.5 80.5 4.42 
 
The calibration curve was established by plotting the peak area ratio versus concentration, which 
was linear over the range of 2.5–100 ng/mL with the regression equation: Y = 0.0028X − 0.0015 
(r = 0.9995, n = 7). The limit of quantification (LOQ) for trimetazidine was 2.5 ng/mL. In 
addition, the intra-day and inter-day precision was about 2.84–6.10% (n = 5) and 4.83–5.82%, 
respectively. Accuracy expressed as bias ranged from −3.7% to +3.2% (Table 2). 
 
Table 2: Intra/inter-day accuracy and bias of trimetazidine in human plasma 
Theoretical concentration (ng/mL) Intra-day (n = 5)  Inter-day (n = 5) 
 Mean concentration 
Calculated (ng/mL) 




R.S.D. (%) Bias (%) 
2.5 2.55 4.18 +2.0  2.53 4.91 +1.2 
5 5.15 2.84 +3.0  5.16 4.83 +3.2 
20 19.27 6.10 −3.7  20.00 5.82 0 
80 82.35 3.35 +2.9  79.75 5.77 −0.3 
 
The mean plasma concentration–time curves of two formulations of trimetazidine products on 19 
healthy male Chinese volunteers with a single 20 mg oral dose are shown (Fig. 2). The 
calibration curve is Y = (0.0021 ± 0.0005)X−(0.0010 ± 0.0008) (r = 0.9991, n = 10) and the 
R.S.D. of quality control calculated by these calibration curves is less than 15%. The primary 
pharmacokinetic parameters for both drugs are listed in Table 3. According to the current study, 
the relative bioavailability of the test formulation was 102.6% (Mean AUC0–24) and 102.2% 
(mean AUC0−∞), respectively. There were no significant differences between the two 
formulations on the basis of assessment by a two one-sided t-test. The 90% confidence intervals 
of test to reference ratio of the AUC0–24 were within the bioequivalence criteria range of 80–
125%, and that of Cmax was within 70–143%. Therefore, the two products were bioequivalent. 
 
 
Figure 2: Mean plasma concentration–time curve for trimetazidine after oral administration of 20 mg trimetazidine 
as test and reference formulations in 19 healthy volunteers. 
 
 
Table 3: Main pharmacokinetic parameters after administration of a single oral 20 mg dose of 
trimetazidine in the healthy Chinese volunteers (n = 19) 
Parameters Test tablet Reference tablet 
AUC0–24 (ng h mL−1) 673.1 ± 117.6 652.3 ± 121.9 
AUC0−∞  (ng h mL−1) 717.1 ± 120.9 692 ± 128.6 
Cmax (ng mL−1) 74.85 ± 12.13 71.93 ± 14.32 
Tmax (h) 2.312 ± 0.663 2.211 ± 0.608 
t1/2 (h) 4.785 ± 0.919 4.74 ± 0.823 
Relative bioavailability of test tablet duo to AUC0–24 (%) 103.9 ± 8.8  
Cmax, peak concentration; AUC, area under concentration–time curve and Tmax, time to Cmax. 
 
CONCLUSION 
The proposed LC/ESI-MS method provided a simple assay for the determination of trimetazidine 
in human plasma with good sensitivity and specificity. In the bioequivalence study on Chinese 
volunteers, two 20 mg trimetazidine formulations in the form of tablets were assessed, and the 
statistical comparison of AUC0–24, AUC0−∞ and Cmax obviously showed no significant difference 
between the two formulations. About 90% of log-transformed data for the mean ratio 
(test/reference) of parameters AUC0–24, AUC0−∞ and Cmax for the two formulations were 80–
125%, in the acceptance range of bioequivalence. The present study indicates that these two 
products are bioequivalent in the Chinese population, and the pharmacokinetics of trimetazidine 
in Chinese population does not significantly differ from data obtained from Romania population 
[8]. 
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